PharmX Technologies Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

PharmX Technologies heeft een totaal eigen vermogen van A$16.0M en een totale schuld van A$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk A$29.9M en A$13.9M. De EBIT PharmX Technologies is A$244.0K waardoor de rentedekking 5.7 is. Het heeft contanten en kortetermijnbeleggingen van A$13.1M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

AU$0

Schuld

Rente dekkingsratio	5.7x
Contant	AU$13.14m
Aandelen	AU$15.97m
Totaal verplichtingen	AU$13.89m
Totaal activa	AU$29.86m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?

Apr 29

Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 02

Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Dec 13

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$16.4M ) PHX } overtreffen de korte termijn passiva ( A$12.0M ).

Langlopende schulden: De kortetermijnactiva PHX ( A$16.4M ) overtreffen de langetermijnschulden ( A$1.9M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: PHX is schuldenvrij.

Schuld verminderen: PHX heeft de afgelopen 5 jaar geen schulden gehad.

Schuldendekking: PHX heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: PHX heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

PharmX Technologies Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024

PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate Director

Full year 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2023)

New major risk - Share price stability

PharmX Technologies Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

First half 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2023)

PharmX Technologies Limited to Report First Half, 2024 Results on Feb 23, 2024

Now 27% overvalued

What Is PharmX Technologies Limited's (ASX:PHX) Share Price Doing?

New major risk - Market cap size

New minor risk - Share price stability

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023

New major risk - Revenue and earnings growth

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0 in FY 2022)

Corum Group Limited to Report Fiscal Year 2023 Results on Aug 23, 2023

Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million.

A Look At The Intrinsic Value Of Corum Group Limited (ASX:COO)

At AU$0.044, Is Corum Group Limited (ASX:COO) Worth Looking At Closely?

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

No independent directors

Corum Group Limited, Annual General Meeting, Nov 14, 2022

Full year 2022 earnings released: EPS: AU$0 (vs AU$0.002 in FY 2021)

Corum Group Limited Launches Pharmxchange Platform

No independent directors

Zenith Payments Pty Ltd completed the acquisition Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO).

First half 2022 earnings: EPS and revenues miss analyst expectations

Corum Group Limited to Report First Half, 2022 Results on Feb 10, 2022

Corum Group Limited Announces Resignation of Julian Sallabank as Managing Director

Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million.

Is Now The Time To Put Corum Group (ASX:COO) On Your Watchlist?

Full year 2021 earnings released: EPS AU$0.002 (vs AU$0.001 in FY 2020)

At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?

Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good News

First half 2021 earnings released: EPS AU$0.002 (vs AU$0.001 loss in 1H 2020)

Corum Group Limited to Report First Half, 2021 Results on Feb 24, 2021

Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Corum Group Limited Announces Appointment of Dennis Bastas to the Board of Directors

Corum Group Limited Appoints Eryl Baron as Company Secretary, Effective 3 November 2020

Corum Group Limited Appoints Jayne Shaw to its Board of Directors

Corum Group Limited (ASX:COO) completed the acquisition of remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty. Ltd. and Daleflag Pty Ltd.

Corum Group Limited (ASX:COO) entered into a binding agreement to acquire remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty Ltd and Daleflag Pty Ltd for AUD 7.9 million

Corum Group Limited (ASX:COO) completed the acquisition of an unknown additional minority stake in PharmX Pty Limited from Fred IT Group Pty Ltd.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven